Searchable abstracts of presentations at key conferences on calcified tissues

ba0006lb15 | (1) | ICCBH2017

Consensus paper – Physiotherapy in children with OI

Semler Oliver , Mueller Brigitte , Mekking Dagmar

Physiotherapy is one of the most important therapeutic approaches in Osteogenesis imperfecta (OI) besides medical and surgical treatment. At the moment there are no guidelines and no consensus about appropriate physiotherapeutic concepts for children with OI. In each country different preferences regarding the therapeutic approaches (neuro developmental techniques, active and passive training, treadmill training, pool therapy etc) are used. There are hardly any scientific rese...

ba0005cabs.oc2.1 | Oral Communications | ECTS2016

Prostate cancer microRNAs in extracellular vesicles stimulate osteoclastogenesis

Bijnsdorp Irene , Mulder Jorn , Geldof Albert , Bakker Astrid , de Vries Teun , van Moorselaar Jeroen

Prostate cancer (PCa) is the most common cancer in males. When patients develop metastasis, no curative therapy is available. To find new therapeutic options, it is crucial to understand how PCa cells induce metastasis. Recently, it was shown that PCa cells secrete small extracellular vesicles (EVs) that can be found in the circulation and in bones. Uptake of EVs by other cells may change their behaviour. We previously identified three miRNAs that were uniquely upregulated in ...

ba0003pp128 | Cell biology: osteoblasts and bone formation | ECTS2014

Vitamin K2 (MK-7) is involved in bone and energy homeostasis: Effects on osteoblast, adipocyte and β-cell regulatory loops

Gordeladze Jan Oxholm , Reseland Janne Elin , Moller Mona

Uncarboxylated osteocalcin, allegedly via G-protein coupled receptors, interacts with adipocytes and pancreatic β-cells, thus affecting metabolic homeostasis. Here, we demonstrate that MK-7 directly and indirectly, via osteocalcin, modulates the endocrine functions of both β-cells and adipocytes.• It was shown (by applying the Mir@nt@n-based emulation algorithm) that MK-7 was involved in a network of intracellular regulat...

ba0007p181 | (1) | ICCBH2019

Walking quality of children with healed Perthes disease

Jamil Kamal , Fuller Joel , Li Jamie , Bucknell Michael , McKay Marney , Baldwin Jennifer , Burns Joshua , Munns Craig , Pacey Verity

Objectives: Children with Perthes disease may present with altered walking patterns even at the healed stage of the disease. The aim of the study was to assess the walking endurance, fatiguability and gait changes of children with healed Perthes disease, and to determine if walking endurance is associated with hip function and quality of life.Methods: Fifty-one children (38 males) aged 8–16 years with >3 years post-diagnosis of Perthes disease c...

ba0005p374 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

Long term follow-up of fracture incidence and fracture prediction from bone mineral density

Trajanoska Katerina , de Jonge Ester A L , Kieboom Brenda C T , Mulder Marlies , Stricker Bruno H C , Franco Oscar H , Uitterlinden Andre G , Rivadeneira Fernando

Introduction: Due to the ‘greying’ of (industrialized) societies the incidence of osteoporosis and fragility fractures is expected to be increasing. Our aim was to investigate in an elderly population if the incidence of non-vertebral fractures (overall and site specific) has changed after a longer follow-up, and its relation with osteoporosis or osteopenia assessed by bone mineral density (BMD) at baseline.Methods: Incident non-vertebral fract...

ba0003pp319 | Osteoporosis: treatment | ECTS2014

Perceived vs objective knowledge in patients with osteoporosis

Miller Amanda , Thompson Kara , Cole Jenneth , Kaiser Stephanie

Previous studies have demonstrated that patients with osteoporosis (OP) have a poor understanding of their bone disease and that this negatively influences treatment decisions and medication compliance. The aim of this study is to determine if there is a discrepancy between perceived and objective disease knowledge (PK and OK, respectively) in patients with OP and whether this correlates with certain patient characteristics.Design and methods: After ethi...

ba0001pp432 | Osteoporosis: treatment | ECTS2013

Effects of a mutated sclerostin peptide on bone and lean mass in mice

Gerbaix Maude , Pierroz Dominique , Bonnet Nicolas , Boschert Verena , Mueller Thomas , Ferrari Serge

Sclerostin, a product of osteocytes, is known to inhibit Wnt signaling by binding the LRP5/6 receptor.We investigated the effects of a mutated mouse sclerostin protein (muScl, R118A/R144A) with potential sclerostin antagonistic activity. In vitro, muScl fully competed with wild type sclerostin for binding to LRP6, whereas its IC50 for Wnt3a activity was 4× higher than sclerostin (i.e. 600 nM). Moreover, serum osteocalcin increased in mice a...

ba0001pp216 | Cell biology: osteoclasts and bone resorption | ECTS2013

Glycosaminoglycan sulfation is a key regulator of osteoclast biology and osteogenic bone cell signaling

Salbach-Hirsch Juliane , Tsourdi Elena , Ziegler Nicole , Hintze Vera , Scharnweber Dieter , Moller Stephanie , Schnabelrauch Matthias , Rauner Martina , Hofbauer Lorenz

In light of prolonged life expectancy, the need for biomaterials that govern bone regeneration increases. Improved bone regeneration and osseointegration can be achieved by funtionalizing implant materials. The extracellular matrix (ECM) affects differentiation of bone cells and is critical for bone regeneration. Here we assessed the role of the natural occurring bone ECM glycosaminoglycans (GAGs) hyaluronan (HA) and chondroitin sulfate (CS), and their sulfated derivatives, on...

ba0001pp442 | Osteoporosis: treatment | ECTS2013

Design of a prospective observational study to evaluate persistence and adherence during denosumab treatment, and patient characteristics in postmenopausal women with osteoporosis in routine clinical practice

Maurille Feudjo Tepie , Moller Gerd , Hadji Peyman , Ferreira Irene , Siddhanti Suresh , Boonen Stephen , Fahrleitner-Pammer Astrid , Papaioannou Nikos

Treatment of postmenopausal osteoporosis (PMO) has been traditionally hampered by poor persistence and adherence to short-term (≤1-monthly) medications. The efficacy of 6-monthly (Q6M) denosumab treatment has been proven in clinical trials, but effectiveness will be dependent on persistence and adherence in routine clinical practice. This study is designed to evaluate real-world persistence and adherence to denosumab, and to establish how this is best assessed in long-ac...